WHO ICTRP trial
Clinical study of adenocarcinoma with apatinib mesylate tablets combined with…
ChiCTR-OPC-17010572 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR-OPC-17010572 |
|---|---|
| Public title | Clinical study of adenocarcinoma with apatinib mesylate tablets combined with chemotherapy as second-line treatment of advanced gastric cancer or gastric esophagus |
| Scientific title | Clinical study of adenocarcinoma with apatinib mesylate tablets combined with chemotherapy as second-line treatment of advanced gastric cancer or gastric esophagus |
| Primary sponsor | Yangzhong People's Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Observational study |
| Phase | Post-market |
| Countries | China |
| Conditions | gastric cancer |
| Interventions | treatment group:limit into the grop and the ruled out |
| Registration date | Jan 1, 1990 |
| Target size | treatment group:100 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: